Hesperos, Inc. appoints new Chief Executive Officer, Dr. James Kronauge I’m excited to join Hesperos as we expand the capabilities of the Human-on-Chip platform enabling drug developers unprecedented insight into specific disease states, especially for rare … Read More
Hesperos, Inc is proud to announce Dr. Virginia Smith’s recent publication in Frontiers in Cell and Developmental Biology which validates the Human-on-a-Chip method to model the rare autoimmune disease, Myasthenia Gravis. Read the full press release below: … Read More
Dr. James J. Hickman elected as Fellow of the National Acadamy of Inventors Hesperos is excited to announce that Chief Scientist, Dr. James J. Hickman, has been elected fellow of the National Academy of Inventors (NAI). … Read More
Human-on-a-chip System for Use in Therapeutic Index Determination and Systemic Toxicity in Pre-clinical Drug Discovery Presented at AAPS 2020 by James J. Hickman, PhD Chief Scientist, Hesperos, Inc.
The Tech Tribune, the journalistic arm of Crunchbase, recently selected Hesperos as one of the top 10 technology startups in Orlando. We are proud to be listed among the best companies in the City Beautiful. Award … Read More
Unraveling the pathologic role of skeletal muscle in ALS A key challenge in developing effective therapies for amyotrophic lateral sclerosis has been a poor understanding of the disease pathology. To address this issue, a team of … Read More
UCF/HESPEROS RESEARCHERS UTILIZE HUMAN-ON-A-CHIP® APPROACH TO MODEL ALS PATHOLOGY Key Findings Data supports use of functional neuromuscular junction (NMJ) system to evaluate amyotrophic lateral sclerosis pathology First study to validate the use of Deanna protocol in … Read More
— New publication in Advanced Science validates potential use in evaluating certain immune responses in drug discovery and systemic diseases, including Coronavirus Disease 2019 (COVID-19)— — Hesperos’ immune system-on-a-chip features recirculating immune cells with the key … Read More